PMS30 THE ECONOMIC CONSEQUENCES OF RHEUMATOID ARTHRITIS: ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS) 2005 AND 2006 DATA
The economic impact of RA is substantial to both income loss and health care costs. Replication and validation of outcomes research are important to establish the precision of statistical associations as well as changes across time. Further study will explore whether changes in the care of patients with RA affect changes in outcomes over time.
PMS31 CLINICAL AND ECONOMIC CHARACTERISTICS OF PATIENTS WITH FIBROMYALGIA
Lachaine J J 1 , Beauchemin C 1 , Landry PA 2 1 University of Montreal, Montreal, QC, Canada, 2 Pfi zer Canada Inc, Kirkland, QC, Canada OBJECTIVES: Fibromyalgia syndrome (FMS) is a chronic disorder defi ned by widespread musculo-skeletal pain that is often associated with a number of comorbidities including fatigue, sleep disturbance, stiffness and functional limitation. In absence of a specifi c diagnostic test, FMS is typically diffi cult to identify, and there is limited knowledge about the economic burden of FMS. The objectives of this study were to estimate prevalence of comorbidities, health care resources utilization and costs associated with FMS. METHODS: A retrospective cohort study was conducted using data from the Quebec provincial health plan (RAMQ) for a random sample of patients with two or more recorded diagnoses of FMS and a control cohort without FMS, matched for age and gender, for a period spanning from June 2006 to July 2007. Prevalence of comorbidities was estimated and a chronic disease score was calculated. Health care resources consumed by FMS and non-FMS patients included visits to physicians, physician's interventions, pain-related medications, non-pain-related medications and hospitalizations. RESULTS: A total of 16,010 FMS patients were identifi ed, with a matched number of control patients. The mean age of the study population was 58.8 years and most subjects were women (67.8%). The prevalence of most comorbidities and the chronic disease score were signifi cantly greater in the FMS patients than in control group (3.8 vs. 2.8; p 0.001). Health resources utilization during the study period was signifi cantly greater among FMS patients than non-FMS patients: the annual number of physician visits and interventions was 25.1 for FMS vs. 14.8 for non-FMS patients. The amount paid by the RAMQ was signifi cantly greater for patients with FMS ($4065) compared to patients without FMS ($2766, p 0.001). CONCLUSIONS: This analysis of the RAMQ database indicated that comorbidities are highly prevalent in FMS patients, and suggested that the economic burden associated with FMS is substantial. Tang B g 1 , Changolkar A 2 , McKenzie RS 1 , Piech CT 1 1 Centocor Ortho Biotech Services, LLC, Horsham, PA, USA, 2 SOAL PharmaTech Solutions, LLC, Philadelphia, PA, USA OBJECTIVES: To evaluate the relationship between out-of-pocket (OOP) pharmacy expenses and switching rates among anti-tumor necrosis factor (anti-TNF) agents in patients with rheumatoid arthritis (RA). METHODS: This retrospective study utilized claims for RA patients from the PharMetrics Patient Centric database. The index biologic date was defi ned as the fi rst anti-TNF claim between January 1, 2000 and December 31, 2006. A minimum of 30 months of continuous plan eligibility was required: 6 months prior to and 24 months following the index biologic date. Patients were followed for 24 months after the index biologic date. Switching among anti-TNFs (infl iximab, etanercept, or adalimumab) was recorded. The pharmacy OOP expense was defi ned as the allowed amount minus amount paid. The annual OOP of $500 was used as a cut point to defi ne the high and low OOP groups. RESULTS: A total of 3,086 patients were analyzed (74.5% female; mean age 49.9 years). Half (1597; 51.7%) had an annual pharmacy OOP $500. The mean and median annual OOP expenses for the study population were $929 and $528, respectively. During the study period, 465 (15.1%) patients switched to a different anti-TNF agent. Compared to the lower OOP expense group, patients in the higher OOP group had a higher switching rate (18.0% versus 12.0%, p 0.0001), and shorter time to switch (329 days versus 352 days, p 0.230). In the logistic regression, after controlling for age, gender, co-morbidity, and disease staging, patients in the high OOP group had significantly higher switching rate (odds ratio 1.60, 95% confi dence interval 1.30-1.96). CONCLUSIONS: Higher OOP expenses were associated with higher rates of switching among the anti-TNF agents in the RA patient population. Decision makers may consider such fi ndings in the benefi t design of this therapeutic class. The purpose of this study was to estimate the expected medical cost of a single conservative medical management (CMM) per patient with osteoporotic vertebral compression fracture (VCF) in Japan. METHODS: A questionnaire survey was conducted for Japanese orthopedic surgeons who mainly provide CMM for patients with VCF during their daily clinical practices, and who consented to participating in the survey. Responses to the questionnaire were summarized and the expected medical costs for each therapeutic regimen until recovery per patient
PMS32 HIGHER OUT-OF-POCKET PHARMACY EXPENSE IS ASSOCIATED WITH HIGHER SWITCHING RATES AMONG ANTI-TUMOR NECROSIS FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS

PMS33
BURDEN OF ILLNESS OF CONSERVATIVE MEDICAL MANAGEMENT OF OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES IN JAPAN
